These studies have established SGLT-2 inhibitors and GLP-1 receptor agonists as the two medication classes for the treatment of type 2 diabetes, which do not only provide glycaemic control and body weight reductions without provoking hypoglycaemic episodes, but also show a potential for reducing the risk for a composite endpoint composed of cardiovascular events like acute myocardial infarction, stroke, cardiovascular death (major adverse cardiovascular events or MACE) in the majority of studies1–3,10,11,13,14,16. The gene discussed is GLP1R; the disease is myocardial infarction.